Literature DB >> 10527248

Nosocomial pneumonia with isolation of anaerobic bacteria in ICU patients: therapeutic considerations and outcome.

R Robert1, G Grollier, P Doré, M Hira, E Ferrand, J L Fauchère.   

Abstract

PURPOSE: Evaluate the influence of the anti-anaerobic antimicrobial therapy in the outcome of patients with nosocomial pneumonia.
MATERIALS AND METHODS: The population study included 53 intensive care unit patients with nosocomial pneumonia in whom, using a protected specimen brush, anaerobic bacteria were isolated, which were associated or not with aerobes. Current and empirical antibiotherapies were retrospectively analyzed, regarding their efficacy against anaerobic bacteria. Since it was debated, sensitivity to cefotaxime, ceftazidime, and ciprofloxacin was determined in 38 strains of Prevotella species. Outcome was evaluated 10 days after the day of protected specimen brushes. Improvement was defined as a decrease of Murray score or ventilator weaning.
RESULTS: The most frequently isolated bacteria were Prevotella species, which were more frequently resistant to cefotaxime (37%), ceftazidime (50%), and ciprofloxacine (32%) than usually reported in the literature. Sixty-six percent of these strains produced beta-lactamase. The effect of empirical anti-anaerobic antibiotherapy on the outcome at day 10 was evaluable in 39 patients. Twenty-nine patients were improved and 10 patients worsened. Interestingly, patients who had received well-adapted antibiotics against anaerobes had a better outcome after 10 days (P < .02).
CONCLUSIONS: This study suggests that specific antianaerobic therapy may be considered in the choice of empirical antibiotherapy in patients with nosocomial pneumonia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527248     DOI: 10.1016/s0883-9441(99)90023-0

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  8 in total

1.  Anaerobic Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  Protected telescopic catheter also allows anaerobic bacteria isolation in patients with ventilatory-acquired pneumonia.

Authors:  René Robert; Hodanou Nanadoumgar; Delphine Chatellier; Anne Veinstein; Jean-Pierre Frat; Ghislaine Grollier
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

3.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

4.  Optimizing fluoroquinolone utilization in a public hospital: a prospective study of educational intervention.

Authors:  K Lacombe; S Cariou; P Tilleul; G Offenstadt; J L Meynard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

Review 5.  Nosocomial pneumonia in pediatric patients: practical problems and rational solutions.

Authors:  Heather J Zar; Mark F Cotton
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Colonization of lower respiratory tract with anaerobic bacteria in mechanically ventilated patients.

Authors:  René Robert; Ghislaine Grollier; Jean-Pierre Frat; Cendrine Godet; Michèle Adoun; Jean-Louis Fauchère; Pierre Doré
Journal:  Intensive Care Med       Date:  2003-04-16       Impact factor: 17.440

7.  Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

Authors:  Coleman Rotstein; Gerald Evans; Abraham Born; Ronald Grossman; R Bruce Light; Sheldon Magder; Barrie McTaggart; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

Review 8.  Nosocomial pneumonia : rationalizing the approach to empirical therapy.

Authors:  Gunnar I Andriesse; Jan Verhoef
Journal:  Treat Respir Med       Date:  2006
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.